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Abstract 
Streptococcus pyogenes is a major human pathogen responsible for numerous diseases ranging from 
uncomplicated skin and throat infections to severe, life threatening invasive disease such as necrotising 
fasciitis and streptococcal toxic shock syndrome. These severe invasive infections progress rapidly and 
produce high rates of morbidity and mortality despite the implementation of aggressive treatment plans. 
The activation of plasminogen and the acquisition of plasmin activity at the bacterial cell surface is 
critical for the invasive pathogenesis of this organism. To facilitate this process, S. pyogenes secrete 
streptokinase, a potent plasminogen activating protein. Here, we describe the role of streptokinase in 
invasive pathogenesis and discuss some potentially useful strategies for disruption of streptokinase 
mediated plasminogen activation which could be employed to treat severe invasive S. pyogenes 
infections. 
Keywords 
pyogenes, targeting, streptococcus, therapeutic, determinant, virulence, streptokinase, role, potential, 
CMMB 
Disciplines 
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences 
Publication Details 
McArthur, J. D., Cook, S. M., Venturini, C. & Walker, M. J. (2012). The role of streptokinase as a virulence 
determinant of streptococcus pyogenes - potential for therapeutic targeting. Current Drug Targets, 13 (3), 
297-307. 
This journal article is available at Research Online: https://ro.uow.edu.au/scipapers/4736 
 1
Title: The role of streptokinase as a virulence determinant of Streptococcus 
pyogenes – potential for therapeutic targeting. 
 
 
Jason D. McArthur, Simon M. Cook, Carola Venturini and Mark J. Walker 
 
School of Biological Sciences, University of Wollongong, Wollongong, NSW, 2522, 
Australia 
 
 
 
 
Corresponding author: Professor Mark J. Walker, School of Biological Sciences, 
University of Wollongong, Wollongong, NSW, 2522, Australia. Tel: 0061-2-4221 
3439; Fax: 0061-2-4221 4135; E-mail: mwalker@uow.edu.au 
 
 
 2
 
Abstract 
 
Streptococcus pyogenes is a major human pathogen responsible for numerous diseases 
ranging from uncomplicated skin and throat infections to severe, life threatening 
invasive disease such as necrotising fasciitis and streptococcal toxic shock syndrome.  
These severe invasive infections progress rapidly and produce high rates of morbidity 
and mortality despite the implementation of aggressive treatment plans.  The 
activation of plasminogen and the acquisition of plasmin activity at the bacterial cell 
surface is critical for the invasive pathogenesis of this organism.  To facilitate this 
process, S. pyogenes secrete streptokinase, a potent plasminogen activating protein.  
Here, we describe the role of streptokinase in invasive pathogenesis and discuss some 
potentially useful strategies that disrupt streptokinase mediated plasminogen 
activation and could be employed to treat severe invasive S. pyogenes infections. 
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Streptococcus pyogenes Infections 
 
Streptococcus pyogenes (Group A streptococcus; GAS) is a Gram-positive, β-
hemolytic human pathogen associated with diverse infections ranging from 
asymptomatic mild respiratory and skin ailments such as pharyngitis and impetigo to 
life-threatening forms of invasive disease such as necrotising fasciitis and 
streptococcal toxic shock syndrome.  Superficial self-limiting infection of the upper-
respiratory tract is the most common disease manifestation of GAS infection. 
Systemic diseases arise from the capacity of GAS to degrade and cross epidermal and 
mucosal barriers and invade deep subcutaneous tissues. Although invasive GAS 
disease is much less common, its significance remains high due to the rapidity of 
spread and severity of symptoms [1-3].  The overall burden of GAS disease 
worldwide is of significant concern [2,4]. Acute post-streptococcal glomerulonephritis 
and acute rheumatic fever are immunologically mediated post-streptococcal non-
suppurative sequelae that often follow repeated GAS infection and are a cause of 
morbidity and mortality in children and young adults worldwide [5,6]. 
 
GAS disease can be successfully treated by use of antimicrobial agents and since the 
introduction of penicillin in the 1940s, rates of GAS infections declined over time 
until the mid-1980s when a resurgence of invasive infections was observed. 
Outbreaks of rheumatic fever, toxic shock syndrome and severe skin infections have 
been reported worldwide in the past three decades [5-9].  There is an established non-
random relationship between certain serotypes and streptococcal disease type 
[2,5,8,10,11], and even though host genetic/immune predisposition plays an equally 
important role in the emergence of severe invasive disease in an individual [12,13], 
evolution of bacterial pathogenic potential seems to have driven this epidemiological 
change. 
 
M1, M3 and M18 types in particular have shown a strong association with invasive 
disease cases in the USA and Europe [6,9,14-16] while in indigenous Australian 
populations the correlation between severe disease and specific M types is less 
defined and more complex [4,17].  In particular the M1T1 serotype is the most 
frequently isolated GAS type in clinical cases worldwide and has been associated both 
with non-invasive and invasive disease [11,18,19].  Due to the acquisition of novel 
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lysogenic bacteriophages, this globally disseminated M1T1 clone contains in its 
genome a unique array of virulence determinants in comparison to those found in 
strains of the M1 serotype with which M1T1 shares its chromosomal content. The 
M1T1 clone carries the bacteriophage-encoded speA and sda1 virulence genes but not 
the speC gene found in the genome of M1 GAS strain SF370 [18,20-22].  
 
S. pyogenes virulence factors 
 
GAS possess many putative and defined virulence factors implicated in disease 
development, including both extracellular proteins and surface-exposed molecules 
that play a role in adherence to host tissues, in host immune system evasion and in 
bacterial dissemination. Several reviews describing in detail the proven and 
hypothesized functions of GAS virulence determinants and their role in disease (see 
[2,5,6,9,23-25]). 
 
At the onset of infection GAS strains colonize the skin and soft-tissues by attaching to 
the host epithelial cells via the interaction of several streptococcal adhesins and 
specific host receptors [5]. Colonization is mostly extracellular although cellular 
invasion by S. pyogenes has been documented [26,27]. Persistence within the host is 
then mediated by virulence factors involved in mechanisms of immune system 
evasion such as disruption or inhibition of complement activation, opsonisation and 
phagocytosis, and degradation of immunoglobulins as well as other host proteins 
[5,23]. These virulence determinants include the hyaluronic acid capsule, M and M-
like proteins, cytotoxins, lysins (SLO), proteases (SpeB; IdeS), DNases (Sda) and 
several secreted streptococcal pyrogenic exotoxins (Spes). The Spes are potent 
microbial stimulants of the immune system also known as superantigens [5,6,28,29]. 
 
Because S. pyogenes is highly adapted to colonize various niches in its human host, 
the expression of virulence genes is tightly regulated in response to growth phase and 
changing environmental cues during infection. The Mga regulon along with the RofA-
like proteins, Rgg and several two-component regulatory systems including the two-
component control of virulence regulatory sensor kinase operon (CovR/S), control the 
level of transcription of most streptococcal virulence determinants [30]. 
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Mechanisms of invasive disease 
 
Invasive GAS disease such as necrotising fasciitis requires bacterial entry into areas 
of the human body that are normally sterile through degradation of internal host tissue 
barriers. A number of secreted GAS proteins potentially play a role in this process by 
degrading DNA, hyaluronic acid deposits, and host proteins [2,5,31]. GAS produces 
several streptodornases, proteins with DNase activity, that are thought to be involved 
in GAS pathogenesis by participating in the clearing of pus at the site of local 
infection and consequently aiding invasion [5,32] and by playing a role in evasion of 
the host immune system through degradation of neutrophil extracellular DNA traps 
[33,34]. Most known streptococcal DNases (types A, C and D) are phage-encoded 
proteins [32,35]. 
 
The broad-spectrum cysteine protease SpeB is an extracellular protein secreted as a 40 
kDa zymogen that is proteolitically cleaved to its 28 kDa active form.  It is found in 
all GAS strains but differentially secreted [5].  SpeB is responsible for cleaving 
cytokine precursors, immunoglobulins, cell receptors and ECM proteins [36-38].  In 
accordance with these properties, inactivation of SpeB in some murine models of 
infection resulted in decreased lethality and reduced dissemination to organs 
highlighting a key role of SpeB activity in GAS virulence [5,39-41]. 
 
The interaction of GAS with human plasminogen 
 
The exploitation of host components to increase the chance of survival and spread 
within the human host is an essential invasive pathogenic mechanism of GAS. Human 
plasminogen is often used by invasive bacteria as a virulence factor and this process 
has been recognized as a critical step in GAS invasion [42-46]. In the healthy host, 
active plasmin dissolves intravascular fibrin clots and participates in the repair and 
remodelling of tissue by activating host extracellular metalloproteases and 
collagenases [47]. These same mechanisms are exploited by GAS to promote 
systemic spread [44,46,48,49]. 
 
Plasmin(ogen) can be bound directly to the GAS cell surface via three known 
receptors, plasminogen-binding group A streptococcal M-like proteins (PAM or Prp) 
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[50,51], α-enolase (surface enolase or SEN) [52] and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), alternatively known either as plasminogen receptor (Plr) or 
streptococcal surface dehydrogenase (SDH) [53,54].  Additionally, plasminogen may 
be indirectly bound to the cell surface through the formation of a trimolecular 
complex consisting of plasminogen, streptokinase and fibrinogen which may bind via 
either plasminogen or fibrinogen receptors [55-57]. Plasminogen bound to the 
bacterial cell surface may also be converted into plasmin through the action of the 
host derived plasminogen activators urokinase (u-PA) and tissue plasminogen 
activator (t-PA) [58], or by the activity of the GAS plasminogen activator 
streptokinase (SK).  SK is a highly efficient plasminogen activator that plays a critical 
role in the invasive pathogenesis of GAS [43,49].  Studies on this protein have 
highlighted the species-specificity of the interaction between GAS streptokinase and 
the human plasminogen activation system [31,46].  Streptokinase production in the 
presence of human plasminogen has been shown to enhance GAS virulence in murine 
models of skin infection [44,45,59]. 
 
Streptokinase; a bacterial plasminogen activator 
 
Plasminogen is the 791-amino-acid zymogen form of the human serine protease 
plasmin.  Plasminogen contains several structural domains, consisting of the amino-
terminal peptide, followed by five kringle domains (K1–K5) and the carboxy-terminal 
serine protease catalytic domain [60].  Lysine-binding sites present in K1, K4, and K5 
are responsible for the interaction of plasminogen with a number of other molecules 
such as fibrin(ogen), plasminogen receptors and other cellular surfaces [60].  The 
circulating, soluble form of plasminogen (Glu-plasminogen) is maintained in a 
compact, closed conformation through lysine-dependent interactions between the 
amino-terminal peptide and kringles K4 and K5 [61,62].  On binding to mammalian 
or bacterial receptors, a conformational change is induced in Glu-plasminogen, 
producing an extended, activation-susceptible form [63].  Cleavage of the Lys77-
Lys78 peptide bond in Glu-plasminogen by plasmin removes the amino-terminal 
peptide domain producing Lys-plasminogen which also displays an extended open 
conformation that is more readily activated [64]. 
 
 7
A range of bacterial pathogens are capable of interacting with human plasminogen 
(see Table 1) [43,65].  This interaction can contribute to the course of an infection 
directly through protease mediated degradation of tissue barriers or by affecting the 
immune response being generated by the host.  In Staphylococcus aureus, which 
secret the plasminogen activating protein called staphylokinase, plasmin activity 
localised on the bacterial cell surface will cleave deposited C3b and IgG from the cell 
thereby inhibiting complement function and opsonisation through a reduction in 
phagocytosis by neutrophils and macrophages [66].  Similarly, S. pyogenes isolates 
are capable of acquiring plasmin activity onto the cell surface but how this effects the 
immune response is yet to be examined [67].   
 
Streptokinase is a 414-residue, plasminogen activating protein secreted by many β-
haemolytic streptococcal species [68].  Streptokinase is composed of three structural 
domains; α (aa 1 to 150), β (aa 151 to 287) and γ (aa 288 to 414) [69].  Each domain 
has a similar structure and displays a typical β grasp fold consisting of a major β sheet 
composed of 5 β strands and an α helix in the α and β domains and 4 β strands and a 
coiled coil segment instead of the α helix in the γ domain [69].  Unlike the human 
plasminogen activators, u-PA and t-PA, which cleave the plasminogen activation 
bond (Arg561-Val562) to generate plasmin, streptokinase lacks intrinsic protease 
activity.  Instead, streptokinase forms a stoichiometric complex with plasminogen and 
through non-proteolytic mechanisms, generates an active site in the bound 
plasminogen molecule to produce an activator complex [70,71].  Upon binding of 
streptokinase to plasminogen, a conformational rearrangement occurs where the N-
terminal Ile1 residue is inserted into the N-terminal binding cleft of plasminogen 
allowing this residue to form a salt bridge with Asp740 of plasminogen and triggering 
the formation of the active site [72,73].  Unlike plasmin formed by the proteolytic 
activation of plasminogen, the activator complex can bind to substrate plasminogen 
and cleave the activation bond to produce plasmin [74].  As streptokinase has a much 
higher affinity for plasmin, plasminogen present in the activator complex will readily 
exchange with free plasmin producing a complex that that will readily activate other 
free plasminogen molecules [75].  The activity displayed by both plasminogen and 
plasmin containing activator complexes is not inhibited by the major mammalian 
plasmin regulators, α2-antiplasmin and α2-macroglobulin [70,76]. 
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Streptokinase alleles of S. pyogenes isolates exhibit considerable genetic diversity 
[77] and form two distinct phylogenetic lineages (cluster 1 and cluster 2) [78,79].  
Streptokinase variation has been linked to strains associated with acute post 
streptococcal glomerulonephritis [80,81] and to strains that exhibit skin tissue tropism 
[78].  However, the biological significance of streptokinase polymorphism in 
streptococcal pathogenesis has not been determined.  It has recently been shown that 
variant streptokinase proteins produced by distinct clinical S. pyogenes isolates 
display differing plasminogen activation capacities [79].  Streptokinase encoded by 
cluster 1 ska alleles readily formed an active complex with soluble plasminogen while 
cluster 2 streptokinase required the formation of a trimolecular complex with 
plasminogen and fibrinogen to display plasminogen-activating capability [79].  The 
phenotypic differences displayed by streptokinase variants suggest that these proteins 
may have differing roles in streptococcal pathogenesis. 
 
Despite such phenotypic differences, mechanisms have been proposed by which all S. 
pyogenes strains with differing ska alleles can acquire plasmin activity onto the cell 
surface.  Plasminogen receptors interact with different regions of the plasminogen 
protein.  PAM binds to plasminogen via interaction with K2 [82], whereas fibrinogen 
and other streptococcal plasminogen receptors (SEN and GAPDH) bind via lysine-
dependent interactions with K1, K4, and K5 [60].  Therefore, in strains that express 
cluster 2 type streptokinase, the active trimolecular complex can only be bound to the 
cell surface via PAM or fibrinogen-binding receptors (FgR) such as M1 (Figure 1A).  
Alternatively, strains that express cluster 1 type streptokinase, which do not require 
fibrinogen to form an active complex with plasminogen, can bind the activator 
complex directly to the bacterial cell surface via plasminogen receptors (PLRs) or 
through an interaction with fibrinogen and fibrinogen receptors (Figure 1B) [79].  
Streptokinase polymorphism and the functional differences displayed by these 
proteins may need to be considered when designing inhibitors that target streptokinase 
mediated plasminogen activation for therapeutic purposes. 
 
Streptokinase as a thrombolytic therapeutic  
 
Occlusion of blood vessels by thrombus (blood clot) is an essential function of 
haemostasis.  During healthy haemostatic function, thrombosis is tightly controlled.  
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In the event of vascular injury, thrombosis is rapidly initiated to prevent blood loss.  
Thrombosis also functions as a defence mechanism to prevent systemic dissemination 
of invasive bacteria by encapsulation in fibrin networks [83].  In the event of 
pathological conditions and/or failure to maintain haemostasis, several cardiovascular 
disease states can arise and are classified into three main categories: atherosclerotic 
heart disease (acute myocardial infarction), cerebrovascular disease (stroke) and 
venous thromboembolism (deep-vein thrombosis and pulmonary embolism) [84-86].  
Globally, the incidence of cardiovascular disease is increasing and represents a major 
cause of disability and mortality [84,87]. 
 
There are numerous strategies available for the treatment of thrombosis.  A common 
approach is thrombolytic therapy which involves the use plasminogen activators to 
dissolve clots, resulting in reperfusion of the occluded blood vessels and improved 
outcomes from disease states [84]. The therapeutic potential of the bacterial 
plasminogen activator, streptokinase, has long been recognised and this activator was 
first trialled as a treatment for acute myocardial infarction in 1958 [88].  Streptokinase 
was first approved by the US Food and Drug Administration (FDA) for the treatment 
of acute myocardial infarction in the mid 1980’s and is now used for the treatment of 
myocardial infarction, pulmonary embolism, deep vein thrombosis, arteriovenous-
cannula occlusions and peripheral arterial occlusions [89]. 
 
The relative cost effectiveness of streptokinase as a fibrinolytic agent has made 
streptokinase one of the most widely used thrombolytic therapeutics [90].  Although 
streptokinase is the most efficient activator of human plasminogen [91], its fibrin 
independent activation mechanism limits the effectiveness of streptokinase as a 
therapeutic.  When administered intravenously, streptokinase will form an activator 
complex with circulating plasminogen which will subsequently begin to generate 
plasmin in the circulation at sites distant to that of occluding clots.  This explosive 
plasmin generation depletes circulating levels of fibrinogen, plasminogen and factors 
V and VIII producing systemic fibrinolysis and a hypocoagulable state, which in turn, 
can lead to non-specific bleeding events.  High levels of circulating plasmin also 
increases the production of bradykinin which leads to a lowering of blood pressure 
[92-94].  As streptokinase is of bacterial origin, it is highly immunogenic, which can 
reduce the effective half-life of the protein in the circulation and can limit the number 
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of times streptokinase can be used to treat a patient [95].  Therefore, in developed 
countries the use of streptokinase has declined in favour of therapeutics based on the 
human plasminogen activators, u-PA and t-PA. 
 
Both u-PA and t-PA are trypsin like serine proteases which activate plasminogen 
directly and are non-immunogenic (Table 2).  u-PA activates both circulating and 
fibrin bound plasminogen, but does not bind to fibrin itself.  u-PA has a half-life of 
15-20 min which results in less systemic fibrinolysis when compared to streptokinase 
[96].  In developed countries, t-PA is the most common fibrinolytic agent used for 
treatment of coronary artery thrombosis, pulmonary embolism and acute stroke [89].  
t-PA is a fibrin specific plasminogen activator which means plasmin production is 
confined to the area of thrombus.  Circulating t-PA is rapidly cleared from plasma 
(initial half-life of 4-10 min) resulting in high rates of re-thrombosis [93].  As a result, 
for greatest efficacy t-PA administration is via an initial bolus injection, followed by 
short continuous infusion [93].  Such large doses can produce systemic fibrinolysis 
and unwanted bleeding episodes, side effects similar to those seen with streptokinase 
treatment.  Therefore, much research has been aimed at improving the efficacy of 
current plasminogen activators or identifying novel activators with more favourable 
plasminogen activation characteristics, some of which have been summarised in Table 
2. 
 
Second generation thrombolytic therapeutics based on streptokinase 
 
Streptokinase is an immunogenic protein and as humans are frequently exposed to 
streptococcal infections, the presence of circulating anti-streptokinase antibodies can 
be detected in most individuals [97].  Upon exposure to purified streptokinase protein 
during thrombolytic therapy, high titres of anti-streptokinase antibodies are generated 
and can be long lasting (up to 54 months) [95].  High levels of circulating anti-
streptokinase antibodies reduce the effectiveness of repeat streptokinase therapy by 
rapidly neutralising streptokinase upon administration or by causing numerous 
allergic complications [98,99].  A number of antigenic regions have been identified 
within the streptokinase protein by using murine monoclonal antibodies or patient sera 
[100-103].  Targeting these regions with deletion or site directed mutagenesis has 
been proposed as possible mechanisms by which the immunogenicity of streptokinase 
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can be reduced.  An obvious requirement with this approach is to retain the 
plasminogen activating properties of native streptokinase.  Parhami-Seren et al. [104] 
used naturally occurring variants of streptokinase from different strains of group G 
and group A streptococcus to determine how amino acid sequence variation in 
previously identified antigenic epitope regions affected antibody binding and 
streptokinase function.  In this study, variant streptokinase proteins which contained a 
Ser138Lys substitution were not recognised by an anti-streptokinase monoclonal 
antibody but displayed normal plasminogen activation activity.  When this amino acid 
change was introduced into therapeutic streptokinase, the mutant protein displayed 
unchanged plasminogen activation activity but was not bound by the anti-
streptokinase mAb [104].  Streptokinase variation in GAS has evolved through the 
interaction of this pathogen with the human fibrinolytic and immune systems.  
Therefore, careful analysis of novel variants in future studies will assist in identifying 
regions that can be mutated for immunogenic purposes without disrupting 
plasminogen activation function. 
 
Attempts to increase the in vivo half-life of streptokinase have utilised chemical 
modifications and site directed mutagenesis.  Plasmin will cleave streptokinase at 
Lys59 and Lys386 producing a 37 kDa intermediate which retains only 16% of the 
plasminogen activation activity of native streptokinase [105].  A Lys59Glu 
streptokinase mutant maintained plasminogen activation activity that was comparable 
to native streptokinase but displayed increased resistance to plasmin proteolysis 
indicating that this variant may have a longer functional half-life in therapeutic 
applications [106].  Similarly, PEGylated streptokinase proteins also maintain good 
activator function but are protected from proteolytic degradation and display 
decreased antigenicity due to increased steric interference [107,108].  Currently, the 
only modified streptokinase approved for human use is acylated plasminogen-
streptokinase activator complex (APSAC; antistreplase) [93].  This therapeutic 
consists of an inactive complex of streptokinase and Lys-plasminogen containing an 
acylated catalytic centre.  Upon injection, APSAC undergoes a controlled deacylation 
before displaying thrombolytic activity which serves to increase the half-life of this 
therapeutic [109].  This allows APSAC to be administered as a rapid, bolus injection 
which is more favourable when compared with the long infusions required with native 
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streptokinase.  However, the higher costs associated with this therapy has limited the 
use of APSAC in clinical settings [93] (Table 2). 
 
Modifying the plasminogen activation characteristics of streptokinase has also been 
attempted to improve the therapeutic potential of this molecule.  Fibrin-independent 
plasminogen activation by the streptokinase-plasminogen activator complex is 
thought to be due to the insensitivity of the activator complex to α2-antiplasmin 
inhibition and due to the ability of the activator complex to activate circulating Glu-
plasminogen in the absence of fibrin [110].  Critical for these characteristics is the α-
domain of streptokinase.  Streptokinase mutants harbouring an N-terminal, 59 amino 
acid deletion (SKΔ59) of the α-domain will only form an activator complex with 
plasmin which is susceptible to α2-antiplasmin inhibition and is a poor activator of 
circulating Glu-plasminogen [111,112].  However, the SKΔ59-plasmin complex will 
readily activate unfolded forms of plasminogen such as Glu-plasminogen in the 
presence of fibrin [111].  When compared to t-PA, this mutated form of streptokinase 
displays less fibrinogen degradation in human plasma and has a greater capacity to 
degrade blood clots in vivo using a murine model of human thrombosis [110].   
 
 
Novel therapeutics for the treatment of invasive S. pyogenes infections 
 
Severe invasive GAS infections include bacteraemia, necrotizing fasciitis and 
streptococcal toxic shock syndrome.  Estimates suggest there are over 660,000 cases 
of invasive GAS infections per year which results in over 160,000 deaths world wide 
[4].  Streptococcal toxic shock syndrome is characterised by hypotension and multiple 
organ failure and may be accompanied by necrotizing fasciitis which is a progressive 
bacterial infection of the skin, subcutaneous tissue and the underlying fascia.  The 
rapidity by which these invasive infections can progress produces high rates of 
mortality (30-70%) despite the implementation of aggressive treatment plans [113].  
Recommended treatment consists of surgical debridement, fluid replacement/blood 
pressure support and high-dose intravenous antibiotic therapy (commonly penicillin 
combined with clindamycin to reduce bacterial production of pyrogenic exotoxins and 
superantigens) [114].  More recently the successful use of polyclonal human 
intravenous immunoglobulin (IVIG) for the treatment of invasive infections has been 
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demonstrated in numerous in vitro studies [12,115-118].  However, the use of IVIG as 
an adjunctive treatment in a clinical setting has been less promising [119,120].  
Therefore, there is a need to develop additional therapeutics that may complement 
current treatments and can restrict the systemic spread of S. pyogenes during the early 
stages of infection. 
 
Plasminogen activation and subsequent acquisition of protease activity onto the cell 
surface of S. pyogenes is critical for invasive disease initiation.  Therefore, the 
possibility exists to target the bacterial factors involved in this process as a means to 
prevent systemic infection.  One possible strategy would be to inhibit streptokinase 
mediated plasminogen activation without affecting physiological plasminogen 
activation mechanisms.  This could be achieved by designing specific inhibitors that 
(1) prevent the initial interaction between streptokinase and plasminogen (2) prevent 
the streptokinase mediated conformational rearrangement of plasminogen that 
exposes the active site or (3) prevent the plasminogen-streptokinase activator complex 
from binding substrate plasminogen. 
 
The majority of physiological interactions involving plasminogen are mediated 
through lysine binding sites located within the various kringle domains.  This includes 
binding to a variety of ligands such as fibrin(ogen), α2-antiplasmin, histidine rich 
glycoprotein, thrombospondin and cellular receptors [60].  Streptokinase binds to Glu-
plasminogen, Lys-plasminogen and plasmin with increasing affinities displaying 
dissociation constants of 130 nM, 10 nM and 12 pM respectively [72,75].  The 
increasing affinity for Lys-plasminogen and plasmin is due to increased lysine binding 
sites interactions which occur as the conformation of plasmin(ogen) becomes more 
open and extended making lysine binding sites within kringle domains more 
accessible for interaction with the C-terminal Lys414 residue of streptokinase [121].  
However, initial binding of streptokinase to the compact closed conformation of Glu-
plasminogen is independent of lysine binding sites [72,122].  As Glu-plasminogen is 
the most prevalent circulating form of plasminogen, inhibiting the lysine independent 
interaction between streptokinase and Glu-plasminogen may represent a potential 
strategy for preventing streptokinase binding to plasminogen with minimal disruption 
to the physiological function(s) of plasmin(ogen). 
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As described earlier, streptokinase mediated plasminogen activation involves the 
formation of an activator complex where streptokinase binds to the catalytic domain 
of plasminogen and induces a conformational rearrangement that activates the 
catalytic site non-proteolytically.  However, the majority of plasmin is generated 
proteolytically by the activator complex converting free plasminogen into plasmin.  
This is achieved through the formation of a substrate recognition exosite in the 
activator complex which mediates the specific recognition of substrate plasminogen 
for proteolytic activation [123].  The α domain of streptokinase contributes to the 
formation of this exosite and is critical for the activator complex to capture, extend 
and process substrate Glu-plasminogen [112,124].  Specifically inhibiting 
streptokinase α domain interactions would therefore hinder streptokinase mediated 
plasminogen activation through numerous mechanisms.  Such a strategy could prevent 
non-proteolytic Glu-plasminogen activation in the activator complex and/or could 
prevent the activator complex acting on substrate Glu-plasminogen molecules 
resulting in an overall reduction in the production of plasmin activity. 
 
Conclusion 
 
Streptokinase is an important streptococcal virulence factor which has a critical role in 
the pathogenesis of invasive streptococcal diseases.  The ability of streptokinase to 
activate host plasminogen to the broad spectrum protease plasmin facilitates the 
acquisition of plasmin activity onto the bacterial cell surface.  Surface bound plasmin 
activity promotes systemic spread of bacterial cells through degradation of tissue 
barriers and through modulation of the host immune response.  Inhibiting this critical 
process by designing specific inhibitors or using antibodies that interfere with 
streptokinase mediated plasminogen activation may help to halt the rapid progression 
of invasive S. pyogenes infections and thus reduce the high morbidity and mortality 
associated with these diseases. 
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Table 1.  Bacterial pathogens that interact with human plasminogen. 
Pathogen Plasminogen 
binding 
Plasminogen 
activation 
Reference 
Bacillus anthracis Y  [125] 
Bifidobacteria Spp. Y  [126] 
Borrelia burgdorferi Y  [127] 
Escherichia coli Y  [128] 
Francisella tularensis Y  [129] 
Haemophilus influenzae Y  [130] 
Helicobacter pylori Y  [131] 
Legionella pneumophila Y Y [132] 
Leptospira Spp. Y  [133] 
Listeria monocytogenes Y  [134] 
Moraxella catarrhalis Y  [130] 
Mycobacterium tuberculosis Y  [135] 
Mycoplasma fermentans Y  [136] 
Neisseria Spp Y  [137] 
Proteus mirabilis Y  [130] 
Pseudomonas aeruginosa Y  [138] 
Salmonella enteritidis Y  [128] 
Staphylococcus aureus Y Y [139] 
Streptococcus pneumoniae Y  [140] 
Streptococcus Spp (group A, C and G) Y Y [141] 
Trichomonas vaginalis Y  [142] 
Yersinia pestis Y Y [143] 
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Table 2: Comparison of thrombolytic agents that currently approved or being developed for human use. 
 
Abbreviations: kDa = KiloDalton, PAI-1 = Plasminogen Activator Inhibitor-1, u-PA = urokinase, t-PA = tissue type plasminogen activator, N/A =  Data Not Available, AMI 
= acute myocardial infarction, * = FDA approved. [89,93,94,96,144-146]  
 
 
Streptokinase* 
Antistreplase 
(APSAC)* 
u-PA* Pro-u-PA 
t-PA 
(Alteplase)* 
rt-PA 
(Reteplase)* 
TNK-PA 
(Tenecteplase)* 
nPA Staphylokinase 
Molecular Weight (kDa) 47 131 32/55 49 68 39.5 65 53.5 16.5 
Source Streptococcus  
equisimilis 
Streptococcus 
equisimilis, 
plasminogen 
anisoylated 
Recombinant, 
human fetal, 
kidney 
Recombinant, 
E. coli or, 
mammalian 
cells 
Recombinant, 
human 
melanoma 
cell line 
Recombinant, 
human 
mutant t-PA 
Recombinant 
plus mutation 
Recombinant 
plus 
mutation 
Staphyloccocus 
aureus 
Plasminogen Activation Indirect Indirect Direct Direct Direct Direct Direct Direct Indirect 
Half-life (min) 20 100 <5 9 5 14 25 57 6 
Fibrin Specificity No No No Yes Yes Yes Yes Yes Yes 
PAI-1 Resistance N/A N/A No No No No Yes No N/A 
Elimination Hepatic Hepatic Renal Hepatic Hepatic Renal Renal Hepatic Hepatic 
Antigenic Yes Yes No No No No No No Yes 
Dosing (AMI treatment) 1 h infusion 
10 min single 
bolus 
1 h infusion 
Bolus, 1 hr 
infusion 
Bolus, 90 
min infusion 
Double bolus Single bolus Single bolus 
Double bolus 
over 30 min 
Hospital Cost/Dose ($US) $300 $1,800 $2,000 >$2,000 $2,200 $2,200 $2,200 $2,200 N/A 
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Tri-molecular complex 
Fg binding Plg binding 
PAM 
M1 
Cluster 2 type Cluster 1 type 
Plg binding 
PLR 
Streptokinase Plasminogen (Plg) Fibrinogen (Fg) Plasmin activity 
Bacterial cell Bacterial cell 
  
 
A B
Fg binding 
FgR 
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Figure 1.  Schematic diagram summarizing the hypothesized pathways of cell surface 
plasmin acquisition by GAS strains expressing different alleles of streptokinase.  A) 
Cluster 2 streptokinase must combine with plasminogen and fibrinogen to form a 
trimolecular complex that exhibits plasmin activity.  The trimolecular complex is 
bound to the cell surface via the interaction between PAM and kringle 2 or via the 
interaction between fibrinogen-binding receptors (FgR) such as M1 protein and 
fibrinogen.  Other GAS plasminogen-binding proteins such as SEN cannot bind this 
trimolecular complex, because the domains K1, K4, and K5 required for interaction 
are involved in the interaction with fibrinogen.  B) Cluster 1-type streptokinase will 
combine with plasminogen to form a complex with plasmin activity.  This complex 
can be bound directly to the bacterial cell surface via plasminogen receptors (PLRs) 
or through an interaction with fibrinogen and fibrinogen receptors (modified from 
McArthur et al.[79]).  
 
 
